Psoriasis Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Psoriasis Drugs Market is Segmented by Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies), Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, and Other Mechanisms of Action), Route of Administration (Oral, Parenteral, and Topical), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Psoriasis Drugs Market Overview
Study Period: 2018-2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.89 %
Psoriasis Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The psoriasis drugs market was valued at USD 13,418 million in 2020, and it is expected to reach USD 23,628 million in 2026, registering a CAGR of 9.89% during the forecast period, 2021-2026.

The COVID-19 pandemic initially had a negative growth impact on the psoriasis market, mainly because of the guidelines published by various regulatory bodies suggesting that patients receiving psoriasis treatment are at more risk of infecting COVID-19. In March 2020, the International Psoriasis Council (IPC) recommended physicians discontinue or postpone the prescription of immunosuppressant medications. However, later in September 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania and 16 other research institutions from the United States and Canada, in collaboration with the National Psoriasis Foundation, created guidelines to care for patients with psoriasis during the coronavirus pandemic. The scientists found no evidence that medical interventions to treat psoriasis and psoriatic arthritis should be interrupted or altered to minimize COVID-19 risks. This guideline is further expected to resume the market growth.

An increasing disease burden and demand for psoriasis medicines in emerging economies and the increase in psoriasis research and pipeline drugs are the major factors responsible for the growth of the market. Novel drugs with oral administration open avenues for needle-averse patients. For instance, Bristol Myers Squibb currently has oral TYK2 inhibitor BMS-986165, the efficacy of which has been found similar to TNF-alpha inhibitors. This should be a driving factor for better uptake among patients averse to injectables.

Also, in February 2019, Janssen Biotech Inc., a biotechnology company, received the United States Food and Drug Administration approved TREMFYA for the treatment of severe plaque psoriasis. In addition, key players in the market are involved in various business strategies such as product launches to expand their product portfolios and gain a competitive edge in the market. For instance, in October 2018, Sun Pharmaceuticals Industries Ltd announced the launch of ‘Ilumya’, a novel plaque psoriasis treatment drug in the market. Owing to the above-mentioned factors, the market is expected to register a high growth rate during the forecast period. However, adverse side effects of most of the existing medication and the high cost of the treatment are the factors expected to hamper the market growth.

Scope of the Report

Psoriasis is a genetic condition that may or may not be present at birth but can also be triggered by certain environmental and genetic factors. Factors such as the changing lifestyles of people and their increased inclination toward alcohol consumption and smoking, unhealthy diets, and sedentary living are making people more prone to this condition. The psoriasis drugs market is segmented by type of treatment (biologic drugs, small molecule systemic drugs, and tropical therapies), mechanism of action (TNF alpha inhibitors, PDE4 inhibitors, interleukin inhibitors, and other mechanisms of action), route of administration (oral, parenteral, and topical), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

The report also offers values (USD million) for segments under type of treatment, mechanism of action, and route of administration, but without the sub-segments in the sections of the mechanism of action segmentation for each country provided in the scope.

By Type of Treatment
Biologic Drugs
Small Molecule Systemic Drugs
Tropical Therapies
By Mechanism of Action
TNF Alpha Inhibitors
Etanercept
Certolizumab Pegol
Adalimumab
Infiximab
Golimumab
PDE4 Inhibitors
Apremilast
Interleukin Inhibitors
Secukinumab
Ustekinumab
Other Interleukin Inhibitors
Other Mechanisms of Action
By Route of Administration
Oral
Parenteral
Topical
Geography
North America
United States (By Type of Treatment, Mechanism of Action, and Route of Administration)
Canada (By Type of Treatment, Mechanism of Action, and Route of Administration)
Mexico (By Type of Treatment, Mechanism of Action, and Route of Administration)
Europe
Germany (By Type of Treatment, Mechanism of Action, and Route of Administration)
United Kingdom (By Type of Treatment, Mechanism of Action, and Route of Administration)
France (By Type of Treatment, Mechanism of Action, and Route of Administration)
Italy (By Type of Treatment, Mechanism of Action, and Route of Administration)
Spain (By Type of Treatment, Mechanism of Action, and Route of Administration)
Rest of Europe (By Type of Treatment, Mechanism of Action, and Route of Administration)
Asia-Pacific
China (By Type of Treatment, Mechanism of Action, and Route of Administration)
Japan (By Type of Treatment, Mechanism of Action, and Route of Administration)
India (By Type of Treatment, Mechanism of Action, and Route of Administration)
Australia (By Type of Treatment, Mechanism of Action, and Route of Administration)
South Korea (By Type of Treatment, Mechanism of Action, and Route of Administration)
Rest of Asia-Pacific (By Type of Treatment, Mechanism of Action, and Route of Administration)
Middle-East and Africa
GCC (By Type of Treatment, Mechanism of Action, and Route of Administration)
South Africa (By Type of Treatment, Mechanism of Action, and Route of Administration)
Rest of Middle-East and Africa (By Type of Treatment, Mechanism of Action, and Route of Administration)
South America
Brazil (By Type of Treatment, Mechanism of Action, and Route of Administration)
Argentina (By Type of Treatment, Mechanism of Action, and Route of Administration)
Rest of South America (By Type of Treatment, Mechanism of Action, and Route of Administration)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Interleukin Inhibitors are Expected to Register a High CAGR During the Forecast Period

Interleukin inhibitors are anticipated to witness the fastest growth during the forecast period. The factors aiding interleukin inhibitors are their improved safety and efficacy when compared to other classes of psoriasis drugs, which is consistently leading to increased adoption among patients. For instance, in 2019, the sales of Taltz grew by 46% to USD 1,366.4 million from USD 937.5 million in 2018. Major approved antibodies targeting Interlunkins include Taltz (Ixekizumab), Cosentyx (Secukinumab), Siliq (Brodalumab), Tremfya (Guselkumab), Ilumya (Tildrakizumab), and SKYRIZI (Risankizumab).

In March 2019, AbbVie Inc., one of the key players in the market, received approval from the Japanese Ministry of Health Labour and Welfare (MHLW) for SKYRIZI (Risankizumab), an interleukin-23 (IL-23) inhibitor for treating plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis, among others. The company also received approval for SKYRIZI as a new treatment for plaque psoriasis in Europe in 2018. All these approvals in the market are further propelling the growth of the segment.

However, as psoriasis is a non-emergency condition, the ongoing COVID-19 pandemic has impacted the market as most of the interleukin R&D activities have been halted to focus on COVID-19 vaccine development.

Psoriasis Drugs Market Trends

North America Dominates the Market and is Expected to do so in the Forecast Period

North America has been one of the worst affected regions by the ongoing COVID-19 pandemic. The growth of the psoriasis market is expected to slow down to some extent because patients are avoiding visiting dermatology clinics for psoriasis treatment. Apart from restrictions on non-emergency medical services, new rules of the governments across this region have forced several players in the dermatology drug market to pause their business operations, which has impacted the growth of the market.

North America is expected to dominate the psoriasis market during the forecast period. In North America, the United States holds the largest market share owing to the high prevalence of psoriasis. As per the article, Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis, published in February 2018, the prevalence of psoriasis was estimated at 128 cases per 100,000 individuals. Other factors that will propel the market include the presence of favorable government initiatives, the presence of developed healthcare infrastructure, etc.

Owing to the increasing prevalence of targeted disease and due to the wide acceptance in North American countries, MC2 Therapeutics, a Europe-based company, in August 2020, signed a collaboration agreement with EPI Health LLC for commercialization of its WYNZORA Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US market. The WYNZORA Cream was approved in July 2020 by the United States Food and Drug Administration (FDA) for the topical indication of plaque psoriasis in adults. The upcoming launch of WYNZORA Cream in the American market may further propel the market growth in this region.

Psoriasis Drugs Market Growth Rate By Region

Competitive Landscape

The psoriasis drugs market is moderately competitive and consists of several key players. With respect to the market share, few of the key players currently dominate the market. Companies are focusing on business expansion in developing regions or emerging markets, such as India, China, and South Korea, by adopting strategies, including alliances and acquisitions, for the development of novel products. For instance, in August 2019, Amgen acquired Otezla, a biopharmaceutical company involved in the production of psoriasis drugs, for a value of USD 13.40 billion. Also, in July 2019, Cipla entered a partnership with Alvotech, a biopharmaceutical company, to commercialize AVT02. AVT02 is an adalimumab biosimilar for plaque psoriasis and rheumatoid arthritis.

Recent Developments

In November 2020, Bristol Myers Squibb received positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis.

In August 2020, Lupin Limited and Mylan launched the biosimilar etanercept Nepexto in Germany after receiving marketing authorization from the European Commission in May 2020 for indications, including psoriatic arthritis and plaque psoriasis.

In July 2020, Fujifilm Kyowa Kirin Biologics received the Japanese regulatory approval for manufacturing and marketing of the first adalimumab biosimilar in the island country for the indication of psoriasis vulgaris, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, entero-Behcet's disease, Crohn's disease, and polyarticular-course juvenile idiopathic arthritis.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies

      2. 4.2.2 Increasing Use of Combination Therapies

      3. 4.2.3 Increase in Psoriasis Research and Pipeline Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Side Effects of Existing Medications

      2. 4.3.2 High Cost of Psoriasis Treatments

      3. 4.3.3 Extensive Drug Development and Approval Process

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Treatment

      1. 5.1.1 Biologic Drugs

      2. 5.1.2 Small Molecule Systemic Drugs

      3. 5.1.3 Tropical Therapies

    2. 5.2 By Mechanism of Action

      1. 5.2.1 TNF Alpha Inhibitors

        1. 5.2.1.1 Etanercept

        2. 5.2.1.2 Certolizumab Pegol

        3. 5.2.1.3 Adalimumab

        4. 5.2.1.4 Infiximab

        5. 5.2.1.5 Golimumab

      2. 5.2.2 PDE4 Inhibitors

        1. 5.2.2.1 Apremilast

      3. 5.2.3 Interleukin Inhibitors

        1. 5.2.3.1 Secukinumab

        2. 5.2.3.2 Ustekinumab

        3. 5.2.3.3 Other Interleukin Inhibitors

      4. 5.2.4 Other Mechanisms of Action

    3. 5.3 By Route of Administration

      1. 5.3.1 Oral

      2. 5.3.2 Parenteral

      3. 5.3.3 Topical

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States (By Type of Treatment, Mechanism of Action, and Route of Administration)

        2. 5.4.1.2 Canada (By Type of Treatment, Mechanism of Action, and Route of Administration)

        3. 5.4.1.3 Mexico (By Type of Treatment, Mechanism of Action, and Route of Administration)

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany (By Type of Treatment, Mechanism of Action, and Route of Administration)

        2. 5.4.2.2 United Kingdom (By Type of Treatment, Mechanism of Action, and Route of Administration)

        3. 5.4.2.3 France (By Type of Treatment, Mechanism of Action, and Route of Administration)

        4. 5.4.2.4 Italy (By Type of Treatment, Mechanism of Action, and Route of Administration)

        5. 5.4.2.5 Spain (By Type of Treatment, Mechanism of Action, and Route of Administration)

        6. 5.4.2.6 Rest of Europe (By Type of Treatment, Mechanism of Action, and Route of Administration)

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China (By Type of Treatment, Mechanism of Action, and Route of Administration)

        2. 5.4.3.2 Japan (By Type of Treatment, Mechanism of Action, and Route of Administration)

        3. 5.4.3.3 India (By Type of Treatment, Mechanism of Action, and Route of Administration)

        4. 5.4.3.4 Australia (By Type of Treatment, Mechanism of Action, and Route of Administration)

        5. 5.4.3.5 South Korea (By Type of Treatment, Mechanism of Action, and Route of Administration)

        6. 5.4.3.6 Rest of Asia-Pacific (By Type of Treatment, Mechanism of Action, and Route of Administration)

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC (By Type of Treatment, Mechanism of Action, and Route of Administration)

        2. 5.4.4.2 South Africa (By Type of Treatment, Mechanism of Action, and Route of Administration)

        3. 5.4.4.3 Rest of Middle-East and Africa (By Type of Treatment, Mechanism of Action, and Route of Administration)

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil (By Type of Treatment, Mechanism of Action, and Route of Administration)

        2. 5.4.5.2 Argentina (By Type of Treatment, Mechanism of Action, and Route of Administration)

        3. 5.4.5.3 Rest of South America (By Type of Treatment, Mechanism of Action, and Route of Administration)

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 AstraZenca

      4. 6.1.4 Biogen Idec

      5. 6.1.5 Boehringer Ingelheim

      6. 6.1.6 Celgene Corporation

      7. 6.1.7 Dr.Reddy`s Laboratories

      8. 6.1.8 Eli Lilly and Company

      9. 6.1.9 Forward Pharma

      10. 6.1.10 Johnson and Johnson (Janssen Biotech Inc.)

      11. 6.1.11 Leo Pharma AS

      12. 6.1.12 Merck and Co. Inc.

      13. 6.1.13 Novartis AG

      14. 6.1.14 Pfizer Inc.

      15. 6.1.15 Stiefel Laboratories Inc.

      16. 6.1.16 Stiefel Laboratories Inc.

      17. 6.1.17 Sunpharmaceutical Industries Limited

      18. 6.1.18 Takeda Pharmaceutical Company Limited

      19. 6.1.19 UCB SA

      20. 6.1.20 Valeant Pharmaceuticals

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Psoriasis Drugs Market market is studied from 2018 - 2026.

The Global Psoriasis Drugs Market is growing at a CAGR of 9.89% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Eli Lilly and Company, Pfizer Inc., Johnson and Johnson (Janssen Global Services, LLC), Novartis AG, Amgen Inc. are the major companies operating in Global Psoriasis Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!